Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase
US5932422A · kind A · utility
7Cited by
4References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 1997 |
| Grant date | Aug 3, 1999 |
| Priority date | — |
| Expiry date | Nov 14, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The expression of ubiquitin carboxy-terminal hydrolase is aberrent in cells that are resistant to treatment with chemical agents. Accordingly, the invention features methods for diagnosing and treating drug resistant cells (e.g., tumor cells) by examining and modulating the expression or activity of UCH.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.